Jan is Executive Chairman and member of the Board of Directors of GentiBio. Previously, he was the CEO and President of Trillium Therapeutics (Nasdaq:TRIL), a clinical stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, and took the company from a $16M market capitalization to a $2.3B acquisition by Pfizer in two years. Before Trillium, Jan was the CEO of Tal Medical, a private clinical-stage neuromodulation company, and a leading partner in the healthcare practice of Bain & Company. In addition to GentiBio, Jan is an Executive Chairman at DEM Biopharma. He holds an MBA from Harvard Business School, and PhD in Economics from the Economic University, Slovakia.

Roy Amariglio is an observer on GentiBio board of directors and  Principal on the Israel team for OrbiMed Advisors LLC, a healthcare investment firm, covering venture capital investments in biotech, medical device, and diagnostics companies. Prior to joining OrbiMed, he was a Director of Mergers, Acquisitions, and Licensing at Bayer HealthCare where he was responsible for Healthcare transactions. While at Bayer, he held several positions of increasing responsibilities in Oncology Marketing and Business Development. Roy received his B.A. in Chemistry and Biology from Tel Aviv University and an M.Sc. and Ph.D. in Molecular Genetics from the Weizmann Institute in Israel, as well as an M.B.A. in Finance and Healthcare Management from the Wharton School of the University of Pennsylvania.

Andrew Levin is board observer on GentiBio Board of Directors. Andrew is a Managing Director and co-leads the Venture Team at RA Capital Management, a healthcare and life sciences focused investment firm. Prior to joining RA, he was a Vice President at H.I.G. BioVentures and served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He received a B.S.E in Mechanical Engineering from Princeton University, a Ph.D. in Biomedical Engineering from the Massachusetts Institute of Technology, and an M.D. from Harvard Medical School.

Nandita Shangari is observer on GentiBio borad of directors. Nandita is a Principal at the Novartis Venture Fund (NVF), a life science investment firm. Prior to joining NVF, she held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah® Global Program Team, helping to bring this novel cell therapy to market.Nandita also held strategic and group head roles in the Novartis Preclinical Investigative Toxicology organization. She received a B.Sc. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada

Abhiram Rao is a GentiBio Board Observer and Vice President at Matrix Capital, a technology and life sciences investment firm. In addition to GentiBio, he is a Board Observer at Maze Therapeutics, AltPep and nference. Prior to Matrix, he held roles in strategy and R&D at Tempus, Illumina, and startups in biotechnology and genomics. Abhiram holds a PhD in Bioengineering from Stanford University where his research focused on early-stage drug discovery leveraging computational and high-throughput experimental technologies. He is an author on over 30 papers in journals including Science and Nature Genetics.

Andy Tran is a GentiBio Board Director and a Vice President that leads and oversees key private biotechnology investments at Matrix Capital, a technology and life sciences investment firm. In addition to GentiBio, he has led investments in and served on the boards of multiple companies including Scribe Therapeutics, Insitro, EQRx, Dyno, and other startups in stealth-mode. Prior to Matrix, he was an Investment Partner at Andreesen Horowitz’s (a16z) Bio Fund investing in early-stage ventures in the life sciences. He has previously held roles at Genentech’s Discovery Oncology R&D department and Morgan Stanley’s investment banking group. Andy was trained as a Bioengineer and Computer scientist at Harvard University, where his research focused on gene therapy and CRISPR genome engineering technologies.

Nathaniel Brooks Horwitz is a is a GentiBio Board Director and Principal at RA Capital Management, a healthcare and life sciences investment firm. He has served as a Director or Observer on the boards of several RA Capital portfolio companies, includingQuench Bio, Eliem Therapeutics, Clear Creek Bio, and multiple stealth-mode ventures. He was previously CEO of Nivien Therapeutics. His writing on biotech and other subjects has been published by The Washington Post, The New York Times, The Atlantic, The Boston Globe, and The Financial Review. Horwitz received an A.B. in Molecular and Cellular Biology from Harvard University.

Michal Silverberg is a GentiBio Board Director and a Managing Director at the Novartis Venture Fund (NVF), a life science investment firm. Prior to joining NVF, she was a Senior Partner at Takeda Ventures and, before that, held roles of increasing responsibility at Novo Nordisk, including Senior Director of Business Development and New Product Commercialization. Since 1998, Michal has held positions in various sectors of the life science industry, including in the Office of the Chief Scientist of Israel, venture capital, and global pharmaceutical and biotech companies. She received her B.A. in Economics and Business Management from Haifa University, her M.B.A from Tel-Aviv University, and her M.S. in Biotechnology from Columbia University.

Carl Gordon is a member of GentiBio Board of Directors. Carl is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm.  He also  serves on the boards of directors of several public and private companies.  Carl received a B.A. in Chemistry from Harvard College, a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a fellow at The Rockefeller University.

Erez Chimovits Chairman and member of GentiBio Board of Directors. Erez is a Partner and Senior Managing Director on the Israel team for OrbiMed Advisors LLC, a healthcare investment firm. Erez has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed, Erez was the CEO of NasVax. Previously, Erez spent more than seven years with Compugen as President of Compugen USA Inc. and Executive VP of Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex, and others. Erez earned his B.Sc., his M.B.A., and his M.Sc. in Microbiology from Tel Aviv University.